-
FDA advisory committee recommends approval for Bristol-Myers Squibb's, AstraZeneca's metreleptin in generalized lipodystrophy
PRINCETON, N.J. — A panel of experts at the Food and Drug Administration has recommended approval for an experimental biotech drug under development by Bristol-Myers Squibb and AstraZeneca for a group of rare metabolic disorders.
-
Lawsuit challenges Calif. Medicaid reimbursement cuts
SACRAMENTO, Calif. — Reimbursement cuts to California's state Medicaid program are the subject of a lawsuit filed last week in San Francisco.
The Professional Pharmacy Alliance and the California Korean American Pharmacists Association filed suit against the California Department of Health Care Services in San Francisco Superior Court over an across-the-board 10% cut in 2011 to the reimbursement rates for most providers under the program, known as Medi-Cal.